Head and Neck Cancer
Conditions
Brief summary
This is a German, observational study in adult participants diagnosed with squamous cell carcinoma of the head and neck (SCCHN) progressing on or after platinum-based therapy, who start a new systemic therapy with nivolumab in 1st line (cohort 2) or ≥2nd line (cohort 1) for the first time, and are treated within the market authorization approval. Participants are to be enrolled into the study no earlier than the decision to initiate treatment with nivolumab and no later than the first dose of nivolumab treatment.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: \- Adult participants (at least 18 years of age at time of treatment decision) * Diagnosis of Squamous cell carcinoma of the head and neck (SCCHN) and participants are progressing on or after platinum-based therapy, administered for locally advanced, metastatic or recurrent disease (Cohort 2: prior platinum-based therapy was administered for locally advanced disease in the adjuvant or primary setting, e.g. radiotherapy) * Diagnosis of SCCHN has been confirmed by histology or cytology (either at initial diagnosis or any time later during the course of the disease) * Treatment decision to initiate a treatment with nivolumab for the first time for the treatment of SCCHN (according to the label approved in Germany) has already been taken
Exclusion criteria
* Current primary diagnosis of a cancer other than SCCHN, ie, a cancer other than SCCHN or cancer of unknown primary (CUP-syndrome) that requires systemic or other treatment, or has not been treated curatively (as per discretion of the investigator) * Previously treated with nivolumab and/or ipilimumab, an anti-PD-1, anti-programmed death ligand 1 (anti-PD-L1), anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways (applicable for any indication) * Currently included in an interventional clinical trial for their SCCHN. Participants who have completed their participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for Overall survival (OS) can be enrolled
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival | Up to 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS) | Up to 5 years |
| Time to progression | Up to 5 years |
| Overall Response Rate (ORR) | Up to 5 years |
| Best overall response rate (BORR) | Up to 5 years |
| Best overall response (BOR) | Up to 5 years |
| Tumor response (Investigator assessed) | Up to 5 years |
| Time to response (TTR) | Up to 5 years |
| Duration of response (DOR) | Up to 5 years |
| Description of socio-demographic characteristics of participants | Up to 5 years |
| Description of clinical characteristics of participants | Up to 5 years |
| Description of management of participants with treatment-related adverse events (AEs) | Up to 5 years |
| Description of incidence of AEs | Up to 5 years |
| Description of Severity of AEs | Up to 5 years |
| Description of management of AEs | Up to 5 years |
| Description of participant-reported outcomes (PROs) and health-related quality-of-life (QoL) of participants using the Functional Assessment of Cancer Therapy - Head & Neck (FACT-H&N) questionnaires | Up to 5 years |
| Overall Survival | Up to 5 years |
| Description of participant-reported outcomes (PROs) and health-related quality-of-life (QoL) of participants using European Quality of Life-5 Dimensions (EQ-5D) questionnaires | Up to 5 years |
Countries
Germany
Outcome results
None listed